Final Agenda
Tuesday, June 30, 2020
10:00 a.m. - 6:00 p.m. EDT
Chair:
Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center
Co-Chair:
James Herman, M.D., University of Pittsburgh
NCI Program Directors:
Lynn Sorbara, Ph.D., and Karl Krueger, Ph.D., National Cancer Institute
| 10:00 a.m. - 10:15 a.m. EDT |
L01: Welcome and Introduction Objective, Charge and Progress Pierre Massion, M.D., Vanderbilt University James Herman, M.D., University of Pittsburgh |
| Part I: 10:15 a.m. - 3:00 p.m. EDT | Site Updates/Progress/Future Study Plans |
| 10:15 a.m. - 10:40 a.m. EDT |
L02: Optimizing DNA Methylation Detection for Early Lung Cancer James Herman, M.D., University of Pittsburgh |
| 10:40 a.m. - 10:45 a.m. EDT | Q&A |
| 10:45 a.m. - 11:10 a.m. EDT |
L03: The BU-UCLA Lung Cancer Biomarker Development Laboratory Marc Lenburg, Ph.D., Boston University |
| 11:10 a.m. - 11:15 a.m. EDT | Q&A |
| 11:15 a.m. - 11:40 a.m. EDT |
L04: Steve Dubinett, M.D., University of California, Los Angeles |
| 11:40 a.m. - 11:45 a.m. EDT | Q&A |
| 11:45 a.m. - 12:10 p.m. EDT |
L05: Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer Louise Showe, Ph.D., Wistar Institute |
| 12:10 p.m. - 12:15 p.m. EDT | Q&A |
| 12:15 p.m. - 1:00 p.m. EDT | Lunch Break |
| 1:00 p.m. - 1:25 p.m. EDT |
L06: Quantitative Imaging and Radiomics in the Early Detection of Lung Cancer Matthew Schabath, Ph.D., Moffitt Cancer Center |
| 1:25 p.m. - 1:30 p.m. EDT | Q&A |
| 1:30 p.m. - 1:55 p.m. EDT |
L07: Harvey Pass, M.D., New York University/Langone Medical Center |
| 1:55 p.m. - 2:00 p.m. EDT | Q&A |
| 2:00 p.m. - 2:25 p.m. EDT |
L08: Non-coding RNAs (ncRNAs) as Biomarkers for Early Detection of Non-Small Cell Lung Cancer in Sputum Sanford Stass, M.D., University of Maryland |
| 2:25 p.m. - 2:30 p.m. EDT | Q&A |
| 2:30 p.m. - 2:55 p.m. EDT |
L09: Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center |
| 2:55 p.m. - 3:00 p.m. EDT | Q&A |
| 3:00 p.m. - 3:15 p.m. EDT | Break |
| Part II: 3:15 p.m. - 5:30 p.m. EDT |
Discussion should focus on SWOT (Strengths, Weaknesses, Opportunities, and Threats) What are the strengths of the EDRN and what can we do to further strengthen the Network; Identify weaknesses and discuss the solutions (mitigation); Discuss opportunities and highlight prioritized opportunities; Discuss threats (competing interests/research) and mitigations. Potential discussion topics in the context of SWOT: How do we envision the collaboration with industry as a way of the future; What can we do to focus more attention on including minorities in all biomarker testing and evaluation; What are the ways that we can tap into and engage with many of the other CBRG and DCP programs, i.e., CIB, MCL, Tumor Atlas; Discuss increasing the capacity for accrual for future studies; How can we expand the role of the BRLs? Discuss the potential of another collaborative group that is focused on common assays/technologies/biomarker validation? Can the EDRN consider the integration of small clinical trials to move clinical utility forward? How can we best bring junior investigators in our collaborative group; How do we increase the number of collaborations between our lung collaborative group members? Is EDRN ready to apply Universal Cancer Approach - multianalyte for Pan Cancer Detection? |
| 5:30 p.m. - 6:00 p.m. EDT |
Summary Write up Drs. Pierre Massion, James Herman, Lynn Sorbara, and Karl Krueger will summarize the information for presentation at the general meeting tomorrow. |
| 6:00 p.m. EDT | Adjourn |